Atara Biotherapeutics

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Atara Biotherapeutics strengthens financial position and advances clinical milestones

Atara Biotherapeutics is strategically positioned to drive growth through financial stability, pipeline advancements, and operational efficiency.
Despite workforce reductions, the company's focus on key clinical milestones and regulatory milestones bodes well for future revenue potential.
Navigating challenges in workforce restructuring and regulatory hurdles, Atara remains focused on leveraging opportunities in CAR-T therapies and autoimmune diseases.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a Cell Therapies in Autoimmune panel discussion at the Citi 18th Annual BioPharma Conference on Thursday, September 7, 2023 at.

Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference

ATRA is going to report topline results of a double-blind, randomized, placebo-controlled phase 2 study in progressive multiple sclerosis in November. Based on strong pathophysiological rationale and very promising early-phase data, including supportive imaging and biomarkers, I expect a positive outcome. ATRA will soon need to raise cash considering very high R&D expenses, but following positive phase 2 results this shouldn't be a problem.

Atara Biotherapeutics: A Speculative Buy On Upcoming Phase 2 Multiple Sclerosis Readout

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.31 per share a year ago.

Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue Estimates

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2023, recent business highlights and key upcoming catalysts. “We are pleased to announce IND clearance for ATA3219, our first allogeneic CAR-T cell product candidate.

Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2023 financial results after market close on Tuesday, August 8, 2023. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to.

Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 at 1:00 p.m. PDT / 4:00 p.m. EDT. A live webc.

Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference

Enochian Biosciences Inc

Pieris Pharma

The world of biotech stocks is notoriously difficult to predict. History is littered with companies that appeared destined for superstar status only to crash and burn.

3 Doomed Biotech Stocks Destined for Disaster

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 4:00 p.m. PDT / 7.

Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced updated effectiveness and safety data for tabelecleucel (tab-cel® or EBVALLO™) from the multicenter Expanded Access Program (EAP) study in Europe. The results will be featured in a poster presentation at th.

Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023

Results from the phase 2 BOLD study, using ATA188 for the treatment of patients with progressive multiple sclerosis, are expected in October of 2023. It is said that the global multiple sclerosis drug market size could reach $34.03 billion by 2031; About 10% of MS patients have PPMS.

Atara: MS Study Data Release And Other Catalysts Make This A Must Watch

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.87 per share a year ago.

Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2023, recent business highlights and key upcoming catalysts. “We are entering an important period of potential value-generating milestones for our prioritized pipeline.

Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release first quarter 2023 financial results after market close on Monday, May 8, 2023. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immu.

Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023

ImmunityBio

In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky.

3 Stocks to Buy That Could Be the Next Biotech Breakthrough

The heavy selling pressure might have exhausted for Atara Biotherapeutics (ATRA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Atara Biotherapeutics (ATRA) Loses -33.02% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 11:10 a.m.

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023 at 12:00 p.m.

Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -18.03% and 99.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Misses Revenue Estimates

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2022, recent business highlights and key upcoming catalysts for 2023.

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress

CASTRES, France & THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Pierre Fabre and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced the transfer of the European Commission (EC) marketing authorization (MA) for EBVALLO™ (tabelecleucel) for patients with relapsed or refractory Epstein‑Barr virus positive post‑transplant lymphoproliferative disease (EBV+ PTLD) from Atara to Pierre Fabre.

Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)

THOUSAND OAKS, Calif.--( BUSINESS WIRE )--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release fourth quarter and full year 2022 financial results after market close on Wednesday, February 8, 2023.

Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023

THOUSAND OAKS, Calif.--( BUSINESS WIRE )--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 36,750 restricted stock units of Atara's common stock to three newly hired employees and stock options to purchase an aggregate of 48,300 shares of Atara's common stock to two such newly hired employees. These awards were approved by the Compensation Committee of Atara's Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of February 1, 2023, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

THOUSAND OAKS, Calif.--( BUSINESS WIRE )--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 66,800 restricted stock units of Atara's common stock to six newly hired employees and stock options to purchase an aggregate of 40,000 shares of Atara's common stock to one such newly hired employee. These awards were approved by the Compensation Committee of Atara's Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of January 3, 2022, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).

Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

THOUSAND OAKS, Calif.--( BUSINESS WIRE )--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:45 PM PST / 6:45 PM EST at the Westin St. Francis Hotel in San Francisco.

Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Agios Pharmaceuticals

Beam Therapeutics

The attraction of all three biotech stocks is their potential.

News for Atara Biotherapeutics Stock (ATRA)